SubHero Banner

Tybost® (cobicistat) – Expanded indication

October 3, 2019 - The FDA approved Gilead Sciences’ Tybost (cobicistat), to increase systemic exposure of atazanavir or Prezista® (darunavir) (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of human immunodeficiency virus (HIV)-1 infection in adults and in pediatric patients: weighing at least 35 kg co-administered with atazanavir or weighing at least 40 kg co-administered with darunavir.

Download PDF